The future of multiple sclerosis: Progression focused therapies and RWE
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS)...
Connecting healthcare data to digital campaigns: Solving the attribution challenge
Launching a pharmaceutical marketing campaign takes months of planning, creative development and...
Mitigating data disruptions in open claims datasets
Healthcare data now accounts for approximately 30% of global data volume and with this surge in...
An integrated approach for deeper insight with both open and closed claims data
Pharma teams are under sharper financial scrutiny and policy pressure than they've been in years,...
Beyond reach: How real-world signals reshape healthcare audience targeting
Why most syndicated healthcare audiences fall short Claims data is the foundation of any credible...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen...
Why underpowered studies are more dangerous than you think
In epidemiology, statistical power determines whether a study can accurately detect an effect of a...
Why 'good enough' data is risky
Real World Data (RWD) is increasingly being incorporated into healthcare and life science research...
Can you trust AI for RWE? HealthVerity eXOs validation study says yes
Artificial intelligence is moving quickly into healthcare research, but one question still comes...
The role of real-world data in advancement of Alzheimer’s treatments
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...